Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
May 10, 2022
Share
Chi Sheng Pharma & Biotech Co., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 282.14 million compared to TWD 239.48 million a year ago. Revenue was TWD 282.14 million compared to TWD 239.48 million a year ago. Net income was TWD 26.12 million compared to TWD 12.72 million a year ago. Basic earnings per share from continuing operations was TWD 0.46 compared to TWD 0.22 a year ago. Diluted earnings per share from continuing operations was TWD 0.46 compared to TWD 0.22 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 